Aim: To investigate the stereoselectivity in human metabolic 3-reduction of tibolone. Methods: Twenty healthy Chinese female volunteers were given a single oral dose of tibolone (2.5 mg), and serial blood samples were collected after treatment. The plasma concentrations of the two pharmacologically active 3-hydroxyl metabolites of tibolone, 3α-hydroxyl-7-methyl-norethynodrel (3α-HMN) and 3β-hydroxyl-7-methyl-norethynodrel (3β-HMN) in plasma were determined by using a validated liquid chromatography-mass spectrometry (LC-MS) method.
Introduction
Tibolone, [7α,17α-7-methyl-17-hydroxyl-19-norpregn-5 (10)-en-20-yn-3-one], also called 7-methyl-norethynodrel (MN), is a synthetic steroid ( Figure 1 ) used in hormone replacement therapy (HRT) for postmenopausal women. Clinical data indicates that tibolone can produce the hormonal effects needed to treat climacteric symptoms and to prevent the long-term effects of menopause without stimulating the breast or endometrial tissues [1] [2] [3] . After administration to women, the compound is quickly metabolized into a 3α-hydroxyl metabolite (3α-hydroxyl-7-methyl-norethynodrel; 3α-HMN) and a 3β-hydroxyl metabolite (3β-hydroxyl-7-methylnorethynodrel; 3β-HMN) by the enzymes 3α/β-hydroxysteroid dehydrogenase in the intestine and the liver [4, 5] . Tibolone itself has weak binding affinities to human estrogen, progesterone and androgen receptors, whereas the two 3-hydroxyl metabolites bind solely to the estrogen receptor, and 3α-HMN is approximately 3 times as effective as 3β-HMN [6] . The clinical merits of tibolone are thought to be a result of the tissue-specific activity of the drug and its main metabolites [7, 8] .
The pharmacokinetics of tibolone in female patients have been studied recently, and the plasma concentrations of 3α-HMN and 3β-HMN were determined by using a gas chromatography-mass spectrometry (GC-MS) method [9] . However, the pharmacokinetics of tibolone metabolism in a Chinese human population have not been studied. The present study was undertaken to investigate stereoselectivity in the phar- macokinetics of tibolone metabolism in healthy Chinese female subjects using a validated liquid chromatography-mass spectrometry (LC-MS) method.
Materials and methods
Subjects Twenty healthy Chinese female subjects ranging in age from 30 to 40 years (36.4±3.6 years), in weight from 47 to 67 kg (56.1±5.8 kg), and in height from 143 to 170 cm (157.1±6.4 cm) were enrolled in the study. All subjects were in good health and underwent a pre-enrolment screening that included ascertaining the subjects' medical history, a physical examination, an electrocardiogram (ECG), laboratory tests and urinalysis. No medication was used by the subjects for at least 2 weeks before the study and alcohol was forbidden within the 72 h before drug administration. Approval was obtained from the Institutional Review Board of the Obstetrics and Gynecology Hospital, Medical Center of Fudan University, Shanghai, and all subjects gave written informed consent.
Clinical protocol After an overnight fast of at least 10 h, subjects took one tablet of Livial, which contained 2. LC-MS analysis of the metabolites in plasma Plasma concentrations of 3α-HMN and 3β-HMN were determined by using a LC-MS method described elsewhere [10] . Plasma samples were derivatized with p-toluenesulfonyl isocyanate after extraction with ethyl acetate. Separation of the two derivatized 3-hydroxyl metabolites was carried out on a Diamonsil C 18 column with a linear gradient elution of mixtures of methanol and ammonia acetate aqueous solution. The analytes were detected with a mass spectrometry detector in the negative selected ion monitoring (SIM) mode.
The limit of quantitation for both 3α-HMN and 3β-HMN was 100 ng/L, and the accuracy was 91.6%-116% for 3β-HMN and 90.4%-104% for 3β-HMN. The inter-day and intra-day coefficients of variation for 3α-HMN and 3β-HMN were less than 13.8% and 11.3%, respectively, over the concentration range 0.1-30 µg/L.
Pharmacokinetic analysis Pharmacokinetic parameters were estimated by using non-compartmental analysis of curves of 3α/β-HMN isomer plasma concentrations versus time. Maximum plasma concentrations (C max ) and the corresponding times (T max ) were read as the coordinates of the highest raw data point for each volunteer. The area under the plasma concentration versus time curve (AUC 0-t ) was estimated by using the linear trapezoidal rule up to the last measurable time. AUC 0-∞ was obtained by adding the part of the area extrapolated to infinity (last measurable concentration/k e ) to AUC 0-t , where k e is the slope of the linear regression analysis of natural log concentrations against time. The elimination half-life (T ½ ) was estimated from the plasma data by using the equation T ½ =0.693/k e . The values were expressed as mean±SD. Differences between 3α-HMN and 3β-HMN in the pharmacokinetic data were evaluated statistically by using the independent-samples t-test. P<0.05 was considered statistically significant.
Results
Plasma drug concentration-time curves After subjects were given tibolone, the mean plasma concentrations of 3α-HMN and 3β-HMN were all below 10 ng/mL, and the mean plasma concentrations of 3α-HMN were much greater than those of 3β-HMN (Figure 2 ). The last time point for which all subjects had measurable concentrations of 3α-HMN and 3β-HMN was 18 h. , respectively. There was no significant difference in T max and T ½ between 3α-HMN and 3β-HMN (P>0.05, Table 1 ). After subjects were given tibolone, the two metabolites both reached peak concentrations in the blood at 1.5 h, and T ½ values for 3α-HMN and 3β-HMN were 7.45±2.03 h and 7.50±1.83 h, respectively. 
Pharmacokinetic parameters of the metabolites

Discussion
The mean pharmacokinetic parameters of 3β-HMN were similar to those found by Timmer et al [9] , whereas the peak plasma concentration of 3α-HMN in our study (8.75±4 .36 µg/L) was much lower than that reported elsewhere for early (14.6±5.4 µg/L) [9] or late postmenopausal women (16.7±6.6 µg/L) [9] . Moreover, the AUC 0-∞ of 3α-HMN in the present study (30.97±14.10 µg·h ) [9] . There was a significant difference between the two 3-hydroxyl metabolites in all mean pharmacokinetic parameters except for T max and T ½ ( Table 1) . The mean C max and AUC 0-t values of 3β-HMN were approximately 59% and 62% lower than that of 3α-HMN, respectively. Mean 3α/3β stereoisomer ratios for plasma concentrations of the two metabolites in 20 subjects ranged from 1.5 to 3.0 after administration (Figure 3) . These results indicate that a stereoselective difference exists in the 3-hydroxylization metabolism of tibolone.
Although a 3α-hydroxylization intensive metabolism was found for the metabolism pharmacokinetics of tibolone in the 20 subjects as a whole (with a mean 3α/3β AUC 0-T ratio of 3.11), two 3α-hydroxyl-poor metabolizers were found in the present study (with 3α/3β AUC 0-t ratios of 0.71 and 0.99; Figure 4 ). Differences in the 3α/β-hydroxylization metabolism of tibolone, as well as desogestrel, by different species of animals have been confirmed by Verhoeven et al [11, 12] : both drugs had mainly 3α-hydroxyl metabolites in rats, but 3β-hydroxyl metabolites in dogs. Because 3α-hydroxysteroid dehydrogenase and 3β-hydroxysteroids dehydrogenase reduce 3-keto steroids, polymorphism for 3α/β-hydroxylization metabolism can be explained by individual differences in 3α-hydroxysteroid dehydrogenase activity and 3β-hydroxysteroid dehydrogenase activity.
